SPOTLIGHT: NeoPharm drug fails Phase II


The bad news keeps coming for NeoPharm. Researchers announced late Friday that its experimental colon cancer drug, LE-SN38, missed its primary tumor-response endpoint in a mid-stage trial. No new patients will be enrolled but patients already receiving the therapy will continue to gets doses. The news comes after the company announced last week it was replacing its CEO after being informed that the company would have to mount a new late-stage study of its brain cancer therapy before it could be considered for approval. Report

Suggested Articles

J&J's EGFR-fighting combo stopped tumor growth in 60% of patients whose lung cancer got worse after taking AstraZeneca's Tagrisso.

Amgen's KRAS inhibitor curbed tumor growth in 88% of patients with non-small cell lung cancer, shrinking tumors in one-third of them.

Novartis is forging ahead with the development of spartalizumab in "many, many other indications" despite the setback.